These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 27160545)
1. Unmet need in diabetic nephropathy: failed drugs or trials? de Zeeuw D; Heerspink HJL Lancet Diabetes Endocrinol; 2016 Aug; 4(8):638-640. PubMed ID: 27160545 [No Abstract] [Full Text] [Related]
2. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate. Kota SK; Meher LK; Jammula S; Kota SK; Modi KD Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543 [TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study. Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957 [TBL] [Abstract][Full Text] [Related]
4. Current controversies in blood pressure in diabetic nephropathy. Ritz E; Schömig M Curr Hypertens Rep; 1999; 1(1):9-10. PubMed ID: 10981035 [No Abstract] [Full Text] [Related]
5. Detecting and controlling diabetic nephropathy: what do we know? Appel G Cleve Clin J Med; 2013 Apr; 80(4):209-17. PubMed ID: 23547091 [TBL] [Abstract][Full Text] [Related]
6. Antihypertensive treatment in nephropathy of type II diabetes: role of the pharmacological blockade of the renin-angiotensin system. Rodby RA Nephrol Dial Transplant; 1997 Jun; 12(6):1095-6. PubMed ID: 9198032 [No Abstract] [Full Text] [Related]
7. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154 [TBL] [Abstract][Full Text] [Related]
8. [Hypertension therapy for type 2 diabetics]. Bönner G MMW Fortschr Med; 2007 Jun; 149(23):45, 47-8. PubMed ID: 18062579 [No Abstract] [Full Text] [Related]
9. [Considerations on the treatment of incipient diabetic nephropathy (lst of 2 parts)]. Pérez Blanco FJ; Manzanares L; Moreno G; Cabello MJ An Med Interna; 1996 Apr; 13(4):193-7. PubMed ID: 8688481 [TBL] [Abstract][Full Text] [Related]
10. National trends in the treatment of diabetic nephropathy in the United States. Ajiboye O; Segal JB J Clin Pharm Ther; 2017 Jun; 42(3):311-317. PubMed ID: 28295491 [TBL] [Abstract][Full Text] [Related]
11. The role of angiotensin receptor blockers in diabetic nephropathy. Sharma AM; Weir MR Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421 [TBL] [Abstract][Full Text] [Related]
12. Antihypertensive treatment and mortality in diabetic patients. What is the evidence? Sawicki PT; Heise T; Berger M Diabetologia; 1997 Jul; 40 Suppl 2():S134-7. PubMed ID: 9248721 [No Abstract] [Full Text] [Related]
13. Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in diabetes? Foreman BH; Chambliss ML J Fam Pract; 2004 Mar; 53(3):241-2. PubMed ID: 15000928 [No Abstract] [Full Text] [Related]
14. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control]. Shionoiri H; Yasuda G; Takizawa T; Shionoiri F Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741 [No Abstract] [Full Text] [Related]
15. Investigational drugs for diabetic nephropathy. Cortinovis M; Cattaneo D; Perico N; Remuzzi G Expert Opin Investig Drugs; 2008 Oct; 17(10):1487-500. PubMed ID: 18808309 [TBL] [Abstract][Full Text] [Related]
16. [Threatened diabetic nephropathy. Early administration of ACE inhibitors and AT1 blockers]. Einecke U MMW Fortschr Med; 2002 Apr; 144(15):14. PubMed ID: 12004443 [No Abstract] [Full Text] [Related]